Revolade is a medication that contains the active ingredient eltrombopag. It is used in the treatment of certain blood disorders, particularly those associated with low platelet counts. Here is a comprehensive description of Revolade (eltrombopag) 25 mg tablets:

Mechanism of Action:

• Eltrombopag is a thrombopoietin receptor agonist, meaning it stimulates the production of platelets in the bone marrow. It binds to and activates the thrombopoietin receptor, leading to an increase in the production and maturation of platelets.

Indications:

• Revolade (eltrombopag) is indicated for the treatment of:
  • Chronic Immune Thrombocytopenia (ITP): A condition characterized by a low platelet count due to the immune system mistakenly destroying platelets.
  • Severe Aplastic Anemia: A disorder in which the bone marrow fails to produce an adequate number of blood cells, including platelets.

Dosage:

• The recommended dosage of Revolade (eltrombopag) can vary based on the specific condition being treated, the patient’s weight, and other individual factors. The tablets are typically taken orally, with or without food.

Administration:

• Revolade tablets should be taken as directed by a healthcare provider. It is important to follow the prescribed dosage and administration schedule.

Efficacy:

• Clinical studies have demonstrated the efficacy of eltrombopag in increasing platelet counts in patients with chronic ITP and severe aplastic anemia. The medication helps reduce the risk of bleeding associated with low platelet counts.

Side Effects:

• Common side effects of eltrombopag may include headache, nausea, diarrhea, elevated liver enzymes, and muscle aches. Serious side effects, although less common, can include liver problems, blood clotting issues, and changes in bone marrow.

Precautions:

• Before starting Revolade, patients should inform their healthcare provider about their complete medical history, current medications, and any liver-related issues. Regular monitoring of liver function is often recommended during treatment.

Contraindications:

• Revolade is generally contraindicated in individuals with a known hypersensitivity to eltrombopag. It should be used with caution in patients with certain liver conditions.

Storage:

• Revolade tablets should be stored as per the manufacturer’s recommendations, ensuring proper temperature and handling to maintain their stability.

Compliance:

• Adherence to the prescribed dosage and administration schedule is crucial for achieving the best therapeutic outcomes with Revolade.

Revolade (eltrombopag) 25 mg tablets provide a valuable treatment option for individuals with chronic ITP and severe aplastic anemia, addressing the underlying issue of low platelet counts. However, the use of this medication should be carefully monitored and managed by qualified healthcare professionals to ensure its safety and efficacy for individual patients.